
Sparsentan (CAS: 254740-64-2), originally developed by Bristol Myers Squibb, is a dual endothelin and angiotensin receptor (AGTR1, EDNRA) antagonist. It is indicated for focal segmental glomerulosclerosis and immunoglobulin A nephropathy, and is approved for the treatment of primary IgA nephropathy in adults,first launched in the US on February 17, 2023.
×